David Segal, Ph.D.
4512 Genome Building
Genome engineering to improve public health.
Almost every disease has a genetic component. Often this information is used only to determine how condemned a person is to develop disease. We would like to use the genetic information to fix the disease. A guiding principle for our work has been to study how nature does what it does, then attempt to use that knowledge to make useful tools to improve public health, either through increased knowledge or therapeutic intervention. Specific research foci in the Segal Lab revolve around engineering zinc finger, TALE, and CRISPR nucleases and transcription factors.
- Designing permanent inactivators of HIV. We are designing CRISPR nucleases to chop up the integrated DNA form of the HIV provirus without affecting any human sequences. Unlike most other anti-HIV therapies, this approach would permanently inactivate the virus. It should also be useful in patients with viruses that use CXCR4, for whom CCR5 entry inhibitors would be ineffective (ie: most infected patients). We are also developing novel delivery methods.
- Manipulating epigenetic mechanisms in Angelman, Prader-Willi, and Dup15q Syndromes. These are rare neurogenetic diseases that cause autism-spectrum symptoms, but their genetics has made them the textbook examples of imprinting disorders. We are using zinc finger-based artificial transcription factors to activate the epigenetically silenced genes in these diseases.
- Manipulating genetic variation in Coronary Artery Disease (CAD). Several genetic variations (SNPs) have been recently associated with an increased risk of CAD. We are using CRISPR nucleases to engineer defined haplotypes into human induced pluripotent stem cells (hiPSC) in order to understand the functional role of these variants. Our approach overcomes the historic barrier of trying to study the affects of specific human mutations in a background of millions of other genetic differences between two individuals.
- Using our genomes to improve public health. Directly, or through collaboration, our research interests span colorectal cancer, breast cancer, neurofibromatosis, Down syndrome, Rett Syndrome, and stem cell reprogramming. We are applying our technology to make improved preclinical animal models of disease, drawing on the strategic strengths of UC Davis in human medicine, veterinary medicine, animal science, and genome science.
- High-throughput investigations of CRISPR-DNA interactions. We continue to develop new methodologies for genome editing, such as methods to study off-target activity of CRISPRs and factors for targeted epigenetic modification. We employ methods of directed evolution for protein engineering and ChIP-seq and RNA-seq to examine the effects of tools on a genome-wide scale.
Johnson, L.M., Du, J., Hale, C.J., Bischof, S, Feng, S., Chodavarapu, R.K., Zhong, X., Marson, G., Pellegrini, M., Segal, D.J., Patel, D.J., Jacobsen, S.E. (2014) SRA/SET domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature, 507:124-128.
Owens, J.B., Mauro, D., Stoytchev, I., Bhakta, M.S., Kim, M.-S., Segal, D.J. and Moisyadi, S. (2013) Transcription activator like effector (TALE) directed piggyBac transposition in human cells. Nucleic Acids Res, 41:9197-9207. (PMID: 23921635)
Mackay, J.P., Segal, D.J., and Crossley, M. (2013) Is there a telltale RH fingerprint in zinc fingers that recognize methylated CpG dinucleotides? Trends Biochem Sci, 38:423.
Segal, D.J. and Meckler, J.F., (2013) Genome Engineering at the Dawn of the Golden Age, Annu. Rev. Genomics Hum. Genet, 14:135–158.
Meckler, J.F., Bhakta, M.S., Kim, M-S., Ovadia, R., Habrian, C.H., Zykovich, A., Yu, A., Lockwood, S.H., Morbitzer, R., Elsäesser, J., Lahaye, T., Segal, D.J., and Baldwin, E.P. (2013) Quantitative Analysis of TALE-DNA Interactions Suggests Polarity Effects, Nucleic Acids Res, 41:4118-4128.
Bhakta, M.S., Henry, I.M., Ousterout, D.G., Theva Das, K., Lockwood, S.H., Meckler, J.F., Wallen, M.C., Zykovich, A., Yu, Y., Leo, H., Xu, L., Gersbach, C.A. and Segal, D.J. (2013) Highly Active Zinc-Finger Nucleases by Extended Modular Assembly, Genome Research, 23:530-538.
Meier, J.L., Yu, A., Korf, I., Segal, D.J. and Dervan, P.B. (2012) Guiding the Design of Synthetic DNA-Binding Molecules with Massively Parallel Sequencing, J Am Chem Soc. 134:17814-17822.
Owens, J.B., Urschitz, J., Stoytchev, I., Dang, N.C., Stoytcheva, Z., Belcaid, M., Maragathavally, K.I., Coates, C.J., Segal, D.J., and Moisyadi, S. (2012) Chimeric piggyBac Transposases for Genomic Targeting in Human Cells. Nucleic Acids Res, 40:6978-6991.
Mackay, J.P., Font, J., and Segal, D.J. (2011) The prospects for designer single-stranded RNA-binding proteins. Nature Struct Mol Biol, 18:256-261 .
Zykovich, A., Korf, I. and Segal, D.J. (2009) Bind-n-Seq: high-throughput analysis of in vitro protein-DNA interactions using massively parallel sequencing. Nucleic Acids Res. 37:e151. (PMC2794170)
Brayer, K.J., Kulshreshtha, S., and Segal, D.J. (2008) The protein binding potential of C2H2 zinc finger domains. Cell Biochem. Biophys., 51:9-19.
Brayer, K.J., and Segal, D.J. (2008) Keep your fingers off my DNA – protein-protein interactions mediated by C2H2 zinc finger domains. Cell Biochem. Biophys., 50:111-131. Review.
Camenisch, T.C., Brilliant, M.H., and Segal, D.J. (2008) Critical parameters for genome editing using zinc finger nucleases. Mini. Rev. Med. Chem., 8:669-676. Review.
Porter, J.R., Stains, C.I., Segal, D.J., and Ghosh, I. (2007) A sensitive split beta-lactamase sensor for the sequence specific detection of DNA methylation. Anal. Chem., 79:6702-6708.
Szczepek, M., Brondani, V., Büchel, J., Serrano, L., Segal, D.J. and Cathomen, T. (2007) Structure-based redesign of the dimerization interface reduces the toxicity of zinc finger nucleases. Nat. Biotechnol., 25:786-793.
Gommans, W.M., McLaughlin, P.M.J, Lindhout, B.I., Segal, D.J., Haisma, H.J, van der Zaal, B.J., & Rots, M.G. (2006) Engineering zinc finger protein transcription factors to down-regulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol. Carcinogenesis, 46:391-401.
Carroll, D., Morton, J.J., Beumer, K.J. & Segal, D.J. (2006) Construction and Testing of Zinc Finger Nucleases. Nat. Protocols, 1:1329-1341.
- FRS 001, Genomics and Gene Therapy: How Genes Control You and How You Can Control Them
- MCB 211, Physical Biochemistry - DNA section
- PHA 225, Gene Therapy
- PHA 250, Functional Genomics: from Bench to Bedside
- MDS 406, Endocrinology, Nutrition, Reproduction, and Genetics- Medical School
- National Institutes of Health
- Department of Defense
- WM Keck Foundation
- B&M Gates Foundation
- Foundation for Angelman Syndrome Therapeutic Foundation for Prader-Willi Research